Navigation Links
New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases
Date:3/4/2015

PAOLI, Pa., March 4, 2015 /PRNewswire/ -- Results of the recent study, Results From a Set of 100 Consecutive Cases Using MarginProbe for Intra-Operative Positive Margin Detection, were presented as part of the general poster session at the 32nd Annual Miami Breast Cancer Conference last week.

The study, conducted by Moshe Papa, MD, FACS, Professor of Surgery at the Sackler School of Medicine at Tel Aviv University, reports an analysis of MarginProbe's efficiency and accuracy when used consecutively to examine excised breast tissue during a lumpectomy. The device was used in 100 consecutive lumpectomy procedures between June 2013 and October 2014. Last year, leading breast cancer national societies announced new guidelines for surgical outcomes that require bringing the patient back for a second procedure: "cancer on ink," according to pathology. According to these guidelines, 64 percent of such repeat procedures were spared by use of the MarginProbe in the study. Overall, eight patients underwent a re-excision lumpectomy procedure. Only three out of 100 patients underwent a re-excision procedure due to failed detection of the margins on the main specimen.   

"The fact that only three out of 100 patients had to undergo a re-excision procedure due to failed detection of cancer on the margins is impressive," said Dr. Papa. "The device was only used on the main specimen in this study so it would be interesting to do a study using MarginProbe on the shavings to determine if the total re-excision rate could be reduced even further."

"We are thrilled to present the results of yet another MarginProbe study that showcase its effectiveness in reducing the number of re-excisions," said Dan Hashimshony PhD, CEO and founder of Dune Medical Devices. "As we grow, and surgeons across the country continue to adopt MarginProbe, we become closer to our goal of drastically reducing repeat surgeries for women undergoing lumpectomies."

The study results were conclusive in determining that MarginProbe is an easy tool to use. When combined with intraoperative and clinical information from specimen radiology and palpitation, the majority of positive margins on the main specimen were identified and re-excision rates were reduced.

About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.

Dune Medical Devices is a privately held company with offices in the U.S. and Israel. For more information, please visit www.dunemedical.com.

Logo - http://photos.prnewswire.com/prnh/20150104/166834LOGO 
Logo - http://photos.prnewswire.com/prnh/20150104/166835LOGO 


'/>"/>
SOURCE Dune Medical Devices
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Advocacy Study Highlights Top Locations for High-Growth Companies
2. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
3. New Study Shows Full Spectrum Endoscopy Procedure Reduces The Miss Rate of Adenomas During Colonoscopy
4. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
5. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
6. Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
7. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
8. Ceregene Reports Additional Efficacy Data From Parkinsons Disease Phase 2b Study
9. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
10. Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency
11. Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2020)... ... February 20, 2020 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Jayant Uberoi, MD, Chesapeake Urology in Baltimore MD, has ... Uberoi has achieved a high level of training and experience with the UroLift® ...
(Date:2/19/2020)... ... ... Aspire Regenerative, a leader in offering therapies that restore healthy tissues in ... event on March 1, 2020. It will take place from 10:30 a.m. to 1:30 ... the event, physicians and pharmacists will lead an informative and insightful discussion on weight ...
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 ... to medicine for everyone affected by diabetes, announced a partnership with VeloCity, a fundraising ... The third annual VeloCity event takes place on May 2nd and begins on the ...
Breaking Medicine Technology:
(Date:2/19/2020)... , ... February 19, 2020 , ... ... of and application deadline for its new Lifestyle Medicine Residency Curriculum (LMRC). The ... integrated implementation into medical residency programs. Driven by resident involvement, the curriculum ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... will highlight its growing product portfolio for lower extremities at the American College ... B. Gonzalez Convention Center. The Trigon® Ti Stand-Alone Osteotomy Wedge Fixation System will ...
(Date:2/15/2020)... (PRWEB) , ... February 14, 2020 , ... ... cleaning products, partnered with Baptist Easley Hospital , a member of Prisma ... patient environments. With PCPLUS, the world-class hospital was able to cut its monthly ...
(Date:2/14/2020)... (PRWEB) , ... February 14, 2020 , ... ... Kubernetes automation solution , further strengthening the company’s support for healthcare organizations using ... of them don’t have the resources or experience to do so,” explained Cloudticity ...
(Date:2/13/2020)... ... February 13, 2020 , ... ... fourth consecutive year, his budget proposes substantial, damaging cuts to foreign affairs, global ... cut to development and diplomacy, slashes USAID global health programs by $3.1B, and ...
Breaking Medicine News(10 mins):